NCT05631249

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

An Interventional and Translational Study Investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.

Conditions

• KRAS P.G12C
• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Sotorasib 120Mg Tab	Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up

Timeline

• Start date: 2022-12-13
• Primary completion: 2027-12-12
• Completion: 2027-12-12
• First posted: 2022-11-30
• Last updated: 2025-05-08

Locations

5 sites across 1 country: France

Regulatory

• FDA-regulated drug study